Rhythm pharmaceuticals exec Cramer sells $130k in shares

Published 30/07/2025, 00:02
Rhythm pharmaceuticals exec Cramer sells $130k in shares

Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, INC. (NASDAQ:RYTM), sold 1,520 shares of common stock on July 29 at a price of $85.93, totaling approximately $130,613. The transaction comes as the $5.6 billion market cap company trades near InvestingPro’s Fair Value estimate, with the stock showing impressive returns of over 75% in the past year.

According to a Form 4 filing with the Securities and Exchange Commission, the sale was executed to cover withholding taxes related to the vesting of restricted stock units. On July 26, Cramer also exercised options to acquire 3,125 shares of Rhythm Pharmaceuticals common stock, and these options had a strike price of $0. The company maintains strong financial health with a current ratio of 3.3 and impressive gross profit margins of nearly 90%.

Following these transactions, Cramer directly owns 20,814 shares of Rhythm Pharmaceuticals. Investors should note that the company is scheduled to report earnings in 7 days, with analysts maintaining a strong buy consensus. Discover more key metrics and 13 additional ProTips with an InvestingPro subscription.

In other recent news, Rhythm Pharmaceuticals has seen several updates regarding its stock ratings and target prices from major financial firms. Canaccord Genuity increased its price target for Rhythm Pharmaceuticals to $105, maintaining a Buy rating, after attending a healthcare conference where obesity treatments were a focal point. BofA Securities also raised its price target to $109, citing positive Phase 2 data for Rhythm’s oral MC4R agonist, bivamelagon, and insights from a pediatric endocrinologist. Citizens JMP set a higher price target of $130, following new data from the Phase 3 TRANSCEND trial and Phase 2 results for bivamelagon. Morgan Stanley (NYSE:MS) reiterated an Overweight rating with a $95 price target, highlighting significant BMI reductions in Phase 2 data for bivamelagon in hypothalamic obesity. Additionally, Goldman Sachs resumed coverage with a Buy rating and a $97 price target, expressing confidence in the potential market size for hypothalamic obesity treatments. These developments reflect a strong interest and optimism in Rhythm Pharmaceuticals’ ongoing research and market potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.